Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.
Emily Viehl, PharmD, BCOP
Advertisement
Articles by Emily Viehl, PharmD, BCOP
Advertisement
Latest Updated Articles
Teclistamab-cqyv Shows Promise in Relapsed/Refractory Multiple Myeloma Following 4 Prior Lines of TherapyPublished: February 16th 2023 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
TACTI-004 Trial Studying Eftilagimod Alfa With Pembrolizumab in Advanced NSCLC to Begin Evaluation
3
UConn’s Medical Writing Certificate Program: It’s Just "Write"
4
Pharmacy Policy Updates for October 2025
5
